PBS listing of Vyndamax®(tafamidis) 61mg for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) with NYHA Class I-II heart failure.
For more detailed information use this link to the PBS website.
Then click on ‘Authority Required‘ (see sample link below) on the PBS website.
Important information for patients accessing VYNDAMAX® (tafamidis) on the Compassionate Access Program
VYNDAMAX® (tafamidis), has been listed on the Pharmaceutical Benefits Scheme (PBS). In order to access your eligibility for VYNDAMAX through the PBS, please speak to your treating consultant at your next scheduled appointment.
Please note there is no requirement to switch immediately from the compassionate access program to PBS supply. Pfizer is working with the cardiologists and haematologists using this program to let them know that they have 6 months to manage the transition from the Access program to PBS supply
Channel None news clip of the launch